scispace - formally typeset
Open AccessJournal ArticleDOI

Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion

Reads0
Chats0
TLDR
It is demonstrated that NPY expression is upregulated in cholangiocarcinoma, which exerts local control on tumor cell proliferation and invasion, andModulation of NPY secretion may be important for the management of cholangsiocARCinoma.
Abstract
No information exists on the role of neuropeptide Y (NPY) in cholangiocarcinoma growth. Therefore, we evaluated the expression and secretion of NPY and its subsequent effects on cholangiocarcinoma growth and invasion. Cholangiocarcinoma cell lines and nonmalignant cholangiocytes were used to assess NPY mRNA expression and protein secretion. NPY expression was assessed by immunohistochemistry in human liver biopsies. Cell proliferation and migration were evaluated in vitro by MTS assays and matrigel invasion chambers, respectively, after treatment with NPY or a neutralizing NPY antibody. The effect of NPY or NPY depletion on tumor growth was assessed in vivo after treatment with NPY or the neutralizing NPY antibody in a xenograft model of cholangiocarcinoma. NPY secretion was upregulated in cholangiocarcinoma compared with normal cholangiocytes. Administration of exogenous NPY decreased proliferation and cell invasion in all cholangiocarcinoma cell lines studied and reduced tumor cell growth in vivo. In vitro, the effects of NPY on proliferation were blocked by specific inhibitors for NPY receptor Y2, but not Y1 or Y5, and were associated with an increase in intracellular d-myo-inositol 1,4,5-trisphosphate and PKCα activation. Blocking of NPY activity using a neutralizing antibody promoted cholangiocarcinoma growth in vitro and in vivo and increased the invasiveness of cholangiocarcinoma in vitro. Increased NPY immunoreactivity in human tumor tissue occurred predominantly in the center of the tumor, with less expression toward the invasion front of the tumor. We demonstrated that NPY expression is upregulated in cholangiocarcinoma, which exerts local control on tumor cell proliferation and invasion. Modulation of NPY secretion may be important for the management of cholangiocarcinoma.

read more

Citations
More filters
Journal ArticleDOI

Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer

TL;DR: The potential of NPY, PENK, and WIF1 as combined epigenetic markers for CRC diagnosis, both in tissue and serum and tested their use as serum biomarkers in other cancers are shown.
Journal ArticleDOI

Liver carcinogenesis: Rodent models of hepatocarcinoma and cholangiocarcinoma

TL;DR: The purpose of this review is to describe the technical and experimental features of the most significant rodent models, highlighting similarities or differences between the corresponding human diseases.
Journal ArticleDOI

Molecular pathogenesis of cholangiocarcinoma.

TL;DR: The scientific progresses made in the last years in defining the molecular pathways implicated in the generation of cholangiocarcinogenesis are described.
Journal ArticleDOI

Animal models of cholangiocarcinoma.

TL;DR: Different animal models of CCA are reviewed, their advantages and deficiencies, as well as features which mimic human CCA, to predict therapeutic response in humans.
Journal ArticleDOI

Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth

TL;DR: Targeting APLNR signaling has the potential to serve as a novel, tumor directed therapy for CCA as inhibition of the apelin/APLNR axis decreases tumor growth in the authors' xenograft model.
References
More filters
Journal ArticleDOI

Analysis of relative gene expression data using real-time quantitative pcr and the 2(-delta delta c(t)) method

TL;DR: The 2-Delta Delta C(T) method as mentioned in this paper was proposed to analyze the relative changes in gene expression from real-time quantitative PCR experiments, and it has been shown to be useful in the analysis of realtime, quantitative PCR data.
Journal ArticleDOI

Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976.

TL;DR: In vitro kinase assays indicated that interference with Ca2+ or its binding site is not responsible for the differential inhibition of PKC isozymes by Gö 6976, and Kinetic analysis revealed that PKC inhibition by Gö 7076 was competitive with respect to ATP, non-competitive withrespect to the protein substrate, and mixed type with respectto phosphatidylserine.
Journal ArticleDOI

H1-receptor antagonists. Comparative tolerability and safety.

TL;DR: A benefit-risk ratio or therapeutic index should be developed for each medication in this class of H1-antagonists, and the magnitude of the beneficial effects should be related to the severity of the unwanted effects, especially in the CNS and cardiovascular system.
Journal ArticleDOI

Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma in the United States: A Population-Based Case-Control Study

TL;DR: Several novel associations with ECC and ICC were identified, including HCV infection, chronic nonalcoholic liver disease, and obesity, all of which are increasing in incidence, and smoking, which were associated only with ICC.
Journal ArticleDOI

Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy.

TL;DR: An emphasis is placed on the importance of critical signaling pathways and postulated interactions, including those of ErbB‐2, hepatocyte growth factor/Met, interleukin‐6/glycoprotein130, cyclooxygenase‐ 2, vascular endothelial growth factor, transforming growth factor‐β, MUC1 and MUC4, β‐catenin, telomerase, and Fas pathways as potential molecular therapeutic targets in cholangiocarcinoma
Related Papers (5)